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Background: Epidemiological studies have reported the preventive effect of vitamin A intake on bladder cancer.
However, the findings are inconsistent. To address this issue we conducted a meta-analysis to investigate the
quantitative effects of vitamin A on bladder cancer.
Methods: We searched MEDLINE and Embase databases and the references of the relevant articles in English to
include studies on dietary or blood vitamin A for the risk of bladder cancer. We performed a meta-analysis using
both fixed-effects and random-effects models.
Results: Twenty-five articles on dietary vitamin A or blood vitamin A were included according to the eligibility
criteria. The pooled risk estimates of bladder cancer were 0.82 (95% CI 0.65, 0.95) for total vitamin A intake, 0.88
(95% CI 0.73, 1.02) for retinol intake, and 0.64 (95% CI 0.38, 0.90) for blood retinol levels. We also found inverse
associations between subtypes of carotenoids and bladder cancer risk.
Conclusion: The findings of this meta-analysis indicate that high vitamin A intake was associated with a lower risk
of bladder cancer. Larger studies with prospective design and rigorous methodology should be considered to validate
the current findings.
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Bladder cancer is the fifth most common cancer among
with an estimated 386,000 new cases and 150,000 deaths
world-wide in 2008 [1]. It has the highest lifetime treat-
ment cost for any cancer [2]. Carcinogens or dietary che-
mopreventive agents can be concentrated in urine and
have prolonged exposure to the bladder epithelium,
making it an ideal target for preventative strategies [3].
Environmental factors, particularly dietary factors,
have been postulated to play important roles in the
etiology of bladder cancer [4]. Vitamin A and retinol are
hypothesized to reduce the risk of bladder cancer due to
their roles in the regulation of cell differentiation and
apoptosis [5]. A previous meta-analysis, including seven
case–control studies and three cohort studies, found no
association of bladder cancer in relation with diets low in
retinol and β-carotene [6]. Since the meta-analysis was
published, epidemiologic studies of vitamin A, retinol* Correspondence: urowang@126.com
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unless otherwise stated.(preformed vitamin A), and carotenoids in relation to
the risk of bladder cancer have documented inconsistent
results. In the present study, we analyzed this relationship
further by conducting an updated meta-analysis of rele-
vant studies. This updated analysis will allow us to pro-
vide more precise risk estimates than the previous
analysis according to different carotenoids. We also
examined the association between blood vitamin A
concentrations and bladder cancer risk.
Methods
Search strategy
We searched MEDLINE and Embase databases to
September 2013 for studies in humans on the relationship
between vitamin A and incidence of bladder cancer. The
search query was the following: (retinol or “vitamin A” or
beta-carotene or carotenoids) and (“bladder cancer” or
“urothelial cancer” or “urinary tract cancer” or “urinary blad-
der neoplasms” [MeSH Terms]). We also reviewed the refer-
ence lists from reviews, meta-analyses and other relevant
publications to search for further studies to be included.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Studies were included in this meta-analysis if they met
the following criteria: they presented original data from
case–control or cohort studies; the exposure of interest
was intake of vitamin A (retinol, carotene, or other
carotenoids) or blood (plasma or serum) levels of vita-
min A; the outcome of interest was bladder cancer or
urothelial cancer; and odds ratio or relative risk esti-
mates with 95% confidence intervals (CIs) (or data to
calculate these) were reported and adjusted for at least
age, sex, and smoking. If the same study was used in
more than one publication, we included the one with
the largest number of cases. Because the overwhelming
majority of tumors occurred in the bladder, and the
renal pelvis and ureter are covered by the same urothe-
lium, the term bladder cancer was used as a synonym for
all neoplasms of the bladder, renal pelvis, and ureter.
Data extraction
Data extracted from each study were the following: the
first author, publication year, country where the study
was carried out, study period, participant sex and age,
sample size, anatomical site of the neoplasm, research
contents, study quality, and adjusted covariates. We used
the odds ratio or relative risk with 95% CI of the highest
intake (or blood level) group for bladder cancer com-
pared with the lowest intake (or blood level) group
reported in each study. Data extraction was conducted
independently by two authors (JT and RW), with dis-
agreements resolved by consensus.
Quality assessment
We assessed the quality of all included studies using the
Newcastle-Ottawa scale. (http://www.ohri.ca/programs/
clinical_epidemiology/oxford.asp). This is an eight-item
instrument that allows for the assessment of the patient
population and selection, study comparability, follow-up,
and the outcome of interest. Interpretation of the scale
is performed by awarding points, or ‘stars’, for high-
quality elements. The stars are then added up and used
to compare study quality in a quantitative manner. The
maximum score is nine points, representing the highest
methodological quality.
Statistical analysis
Depending on heterogeneity between studies, we used
fixed- or random-effects models to calculate summary
risk estimates (REs) and 95% CIs for the highest versus
the lowest levels of vitamin A. Statistical heterogeneity
among studies was evaluated using the Q [7] and I2 [8]
statistic. In the sensitivity analysis, one study at a time
was removed and the rest analyzed to evaluate whether
the results could have been affected significantly by a
single study. We also conducted subgroup analyses bystudy design, sex, geographic area, and source of vitamin
A intake (diet or supplement). If results were reported
for both dietary and total vitamin A (foods and supple-
ments combined), we used the results for total vitamin
A in the main analysis. Publication bias was evaluated
with the use of the Egger’s test [9]. All statistical ana-
lyses were carried out with Stata 11 (StataCorp, College
Station, TX, USA). A two-tailed P-value of less than
0.05 was considered to be statistically significant.Results
A flowchart of the identification of relevant studies is
shown in Figure 1. We identified a total of 418 articles
(168 from Embase and 250 from MEDLINE) in our ini-
tial search. Of these, 386 were excluded after screening
the titles and abstracts because of duplicates, reviews,
and non-relatedness. Seven articles were identified from
the references of relevant studies. The remaining 39
articles were given a more detailed assessment, and 14
studies were excluded because they did not meet the
inclusion criteria. Finally, 25 papers were included in
the present meta-analysis [10-34].
Table 1 shows the main characteristics of all 25 studies
included in the final analysis. The 25 studies were pub-
lished between 1988 and 2013 and involved a total of
11,580 cases. Eleven were cohort studies [14,16,18-20,
23,25,29,31,32,34] and 14 were case–control studies
[10-13,15,17,21,22,24,26-28,30,33]. Fifteen studies were
conducted in North America [10,12,14-16,20-24,28,30,
31,33,34], eight in Europe [11,13,18,19,26,27,29,32], and
two in Japan [17,25]. All 25 studies provided REs adjusted
for at least age, sex, and smoking. Five reports provided
results for blood vitamin A levels [20,24,25,28,32]; three
measured plasma vitamin A levels [24,28,32] and two
measured serum vitamin A levels [20,25]. Some studies
included neoplasms of the urinary tract as cases [11,12,
18,20,25,29,32], most of which were found to involve blad-
der cancer, whereas others selected only bladder cancer.
The quality score of studies ranged from six stars to nine
stars according to the nine-star Newcastle-Ottawa Scale
except for one study by Hung et al. (five stars) [24].High versus low vitamin A intake or blood vitamin A
levels
The analyses of vitamin A intake and bladder cancer risk
were based on 11 studies. Figure 2 shows that results on
vitamin A intake in relation to bladder cancer risk were
inconsistent, with both inverse and positive associations
reported. The pooled RE of bladder cancer for the high-
est versus lowest categories of vitamin A intake was 0.82
(95% CI 0.65, 0.95), suggesting that vitamin A intake was
significantly associated with decreased risk of bladder
cancer. There was moderate heterogeneity among studies
Figure 1 Flowchart of study selection.
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of publication bias (P = 0.057).
The REs for each study and all studies combined for
the highest versus lowest categories of retinol intake or
blood retinol level are shown in Figure 3. High intake of
retinol was associated with a reduced but non-significant
risk of bladder cancer (RE 0.88; 95% CI 0.73, 1.02),
whereas high blood level of retinol was strongly asso-
ciated with reduced risk of bladder cancer (RE 0.64; 95%
CI 0.38, 0.90). There was significant heterogeneity among
studies of retinol intake (P = 0.013; I2 = 53.9%) but not
among studies of blood retinol levels (P = 0.355; I2 = 7.6%).
The P-value for the Egger test of retinol intake was 0.10,
suggesting a low probability of publication bias.
To explore the heterogeneity among studies of vitamin
A intake and bladder cancer, we performed sensitivity
analyses. A sensitivity analysis omitting one study at a
time and calculating the pooled REs for the remaining
studies showed that the study by Bruemmer et al. [15]
substantially influenced the heterogeneity for total vita-
min A intake. After excluding this single study, there
was no study heterogeneity (P = 0.198; I2 = 26.7%), and
the RE for the highest versus lowest category of vitamin
A intake was essentially unchanged (RE 0.88; 95% CI
0.78, 0.97). However, we found no study significantly
influenced the pooled RE for retinol intake.
We also performed subgroup analyses by study design,
geographical region, gender, and source of intake (Table 2).
For total vitamin A intake, when carrying out a stratified
analysis for study design, the summary RE intake be-
came non-significant for cohort studies. A significant
inverse association was observed in North Americanstudies, but not in European and Japanese studies. In a
subgroup analysis by source of vitamin A intake, we ob-
served a significantly decreased risk of bladder cancer in
patients with supplementary intake, but not with dietary
or dietary plus supplementary intake. For retinol intake,
the stratified analysis did not show any statistically signi-
ficant difference in summary estimates between strata.
Unexpectedly, high intake of retinol in women seemed to
increase the risk of bladder cancer significantly, although
only two studies were included in this subgroup.
High versus low carotenoids intake or blood carotenoids
levels
The pooled REs of bladder cancer for the highest versus
lowest categories of carotenoids intake or blood caroten-
oids levels are presented in Table 3. High intake of total
carotenoids, α-carotene, β-carotene, and β-cryptoxanthin
was associated with a significantly lower risk of bladder
cancer. The summary REs of bladder cancer comparing
the highest with the lowest category of intake were 0.67
(95% CI 0.55, 0.79) for total carotenoids, 0.87 (95% CI
0.76, 0.99) for α-carotene, 0.89 (95% CI 0.82, 0.97) for β-
carotene and 0.86 (95% CI 0.73, 1.00) for β-cryptoxanthin.
No significant associations were found between lutein and
zeaxanthin, or lycopene intake and the risk of bladder
cancer. There was a significant reduction in bladder
cancer risk associated with increasing blood level of total
carotenoids (RE 0.43; 95% CI 0.55, 0.79), α-carotene (RE
0.56; 95% CI 0.37, 0.75), β-carotene (RE 0.41; 95% CI 0.05,
0.78), and lutein and zeaxanthin (RE 0.50; 95% CI 0.12,
0.87), whereas no significant association was observed for
β-cryptoxanthin or lycopene.















[10] PCC Canada 1977 to 1982 M/F 35 to 79 826/1,618 Bladder Diet: vitamin A, retinol, β-carotene 7 Age, sex, area of residence, smoking,
history of diabetes
[11] PCC Sweden 1985 to 1987 M/F 40 to 74 418/929 Urothelium Supplement: vitamin A, β-carotene 7 Age, sex, smoking
Diet: retinol
[12] PCC USA 1977 to 1986 M/F 30 to 93 261/783 Urothelium Total: vitamin A, retinol, carotenoids 8 Age, sex, ethics, smoking
[13] PCC Spain 1985 to 1986 M < 80 432/1,224 Bladder Diet: retinol, carotene 8 Age, sex, smoking, total calories
[14] Cohort USA 1981 to 1989 M 65 to 84 71/70,159 Bladder Supplement: vitamin A 5 Age and smoking
Diet: β-carotene
[15] PCC USA 1981 to 1984 M/F 45 to 65 262/667 Bladder Diet: vitamin A, retinol, β-carotene 8 Age, sex, county, smoking, calories




Cohort USA 1986 to 1998 M 40 to 75 320/51,529 Bladder Total: vitamin A 7 Age, energy, pack-years of smoking,
current smoking status, geographic
region of the USA, cruciferous
vegetable intake, total fluid intake
[17] HCC Japan 1996 to 1999 M/F 20 to 99 297/692 Bladder Diet: vitamin A, retinol, carotene 6 Age, sex, smoking, occupational
history as a cook
Total: vitamin A, retinol, carotene
[18] Cohort Netherlands 1986 to 1992 M/F 55 to 69 569/3,692 Urinary tract Total: retinol, α-carotene, β-carotene,
β-cryptoxanthin, lycopene, lutein/
zeaxanthin




Cohort Finland 1985 to 1998 M 50 to 69 344/27,111 Bladder Diet: vitamin A, α-carotene,
β-carotene, β-cryptoxanthin,
lycopene, lutein/zeaxanthin
7 Age, duration of smoking, smoking
dose, total energy, trial intervention




8 Age, sex, smoking




8 Age, sex, education, number of
cigarettes smoked per day, number
of years of smoking, smoking status,
lifetime use of non-steroidal
anti-inflammatory drugs, number of
years employed as a hairdresser/barber
[22] HCC USA 1999 to 2003 M/F Not mentioned 409/860 Bladder Diet: carotenoids, provitamin A,
non-provitamin A
7 Age, gender, ethnicity, smoking status,
pack-years of smoking, total energy
[23] Cohort USA 1980 to 2000 F 30 to 55 237/88,796 Bladder Total: vitamin A, α-carotene,
β-carotene, β-cryptoxanthin,
lycopene, lutein/zeaxanthin
7 Age, pack-years of smoking, current



















Table 1 Study characteristics of published cohort and case–control studies on vitamin A and bladder cancer risk (Continued)




7 Age, sex, smoking, alcohol consumption,
body mass index, total cholesterol,
education
[24] HCC USA 1993 to 1997 M/F Not mentioned 84/257 Bladder Plasma: α-carotene, β-carotene,
β-cryptoxanthin, lycopene,
lutein, zeaxanthin
5 Age, sex, pack-years of smoking,
education
[26] PCC Belgium 1999 to 2004 M/F Not mentioned 178/540 Bladder Diet: retinol 7 Sex, age, smoking status, number of
cigarettes smoked per day, number
of years smoking, occupational
exposure to PAH or aromatic amines,
total fruit and vegetable consumption,
intake of vitamin E and C and total
anti-oxidantstatus
[27] HCC Spain 1998 to 2001 M/F Not mentioned 912/1,789 Bladder Diet: retinol and carotenoids 6 Age, gender, region, smoking status,
smoking duration
[28] HCC USA 1999 to M/F Not mentioned 386/773 Bladder Diet: retinol 6 Age, gender, ethnicity, smoking
status, number of cigarettes per day,
smoking durationPlasma: retinol
[29] Cohort Denmark 1993 to 2006 M/F 50 to 64 322/55,557 Urothelium Diet: β-carotene 8 Age, intake of vitamin C, vitamin E,
and beta-carotene, smoking status,
smoking duration, smoking intensity,
passive smoking, work exposure.
Supplement: β-carotene
Total: β-carotene
[30] PCC USA 1997 to 2001 M/F 25 to 74 322/561 Bladder Total: carotenoids, α-carotene,
β-carotene, β-cryptoxanthin,
lycopene, lutein
8 Age, sex, smoking status, total energy
intake
[31] Cohort USA 2000 to 2007 M/F 50 to 76 330/77,050 Bladder Supplement: β-carotene and
retinol
8 Age, sex, race, education, family
history of bladder cancer, smoking
status/recency of smoking, pack-years
of smoking, servings per day of fruits,
servings per day of vegetables
[33] PCC USA 2001 to 2004 M/F 30 to 79 1,418/2,589 Bladder Diet: vitamin A, α-carotene,
β-carotene
8 Age, gender, region, race, Hispanic
status, smoking status, usual body
mass index, total energy
[32] Cohort (nested) Europe 1990 to 2005 M/F 25 to 70 856/1,712 Urothelium Diet: β-carotene 8 Age at blood collection, study center,
sex, date of blood collection, time of
blood collection, fasting status; further





[34] Cohort USA 1993 to 2007 M/F 45 to 75 581/185,885 Bladder Diet: vitamin A, α-carotene,
β-carotene, β-cryptoxanthin,
lycopene, lutein
8 Age, ethnicity, total energy intake,
family history, employment in a
high-risk industry, smoking, number
of years since quitting, interactions
of ethnicity with status



















Figure 2 Pooled risk estimates of bladder cancer for the
highest versus lowest categories of total vitamin A intake.
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Although vitamin A is found in a wide variety of foods,
many people do not obtain an adequate intake of this nu-
trient. Therefore, the impact of vitamin A intake on blad-
der cancer risk has important public health implications
Our findings were inconsistent with the previous meta-
analysis [6], which suggested that no increased risk of
bladder cancer were found for diets low in retinol (RE
1.01; 95% CI 0.83, 1.23) or beta-carotene (RE 1.10; 95%
CI 0.93, 1.30) intake. We conducted an updated meta-
analysis with results from new epidemiological studiesFigure 3 Pooled risk estimates of bladder cancer for the highest
versus lowest categories of retinol intake or blood retinol level.presented in the past 13 years, and excluded results not
adjusted for age, sex, and smoking. We complemented this
analysis with pooled analyses of each carotenoid and
blood vitamin A levels. The present meta-analysis sug-
gests that increased vitamin A intake is associated with
a reduced risk of bladder cancer. Retinol intake had a
weak, but non-significant inverse association with the
risk of bladder cancer, and carotenoids intake had a
strong inverse association with the risk of bladder can-
cer. Moreover, both the blood total retinol and carot-
enoids levels had a significant association with the
reduced risk of bladder cancer.
A preventive role of vitamin A in the development of
bladder cancer is plausible. Retinol, the physiologically
active form of vitamin A, and its metabolites (retinoids)
play an important role in cell proliferation and differen-
tiation [35]. Synthetic retinoids are effective in the pre-
vention of bladder carcinogenesis in experimental
animals [36]. We found that high retinol intake was as-
sociated with a borderline significant reduced risk of
bladder cancer, and the non-significance might be attrib-
uted to the heterogeneity among studies. The anticarci-
nogenic properties of carotenoids are associated with
their antioxidant activities; their modulation of carcino-
gen metabolism; their effects on cell translation and dif-
ferentiation, cell-to-cell communication and immune
function; and their inhibition of cell proliferation, oncogene
expression and the endogenous formation of carcinogens
[37]. While some carotenoids have potential to form vita-
min A (provitamin A carotenoids, including α-carotene,
β-carotene, and β-cryptoxanthin), others do not have this
capability (non-provitamin A carotenoids such as lycopene,
lutein, and zeaxanthin) [38]. Our results showed a signifi-
cantly reduced risk of bladder cancer with high intake of
α-carotene, β-carotene, and β-cryptoxanthin, but no associ-
ation with lycopene, lutein, and zeaxanthin, suggesting that
provitamin As are responsible for the chemoprotective
effects of vitamin A.
Interestingly, we found that the inverse associations
between vitamin A and risk of bladder cancer were more
evident in blood levels. This may be because of measure-
ment error in the assessment of vitamin A intake from
food frequency questionnaires, leading to an attenuation
of the observed association. By measuring vitamin A in
blood, researchers are able to estimate the internal doses
of nutrients. However, blood level of vitamin A only re-
flects a short-term dietary intake because the half-life of
vitamin A in blood is only a few days. In addition, many
people make changes to their diet by increasing the in-
take of dietary vitamin A after a cancer diagnosis as a
way of staying as healthy as possible, and blood levels of
vitamin A should be higher than before the diagnosis.
This would underestimate the true associations of vita-
min A with bladder cancer and result in bias of the RE
Table 2 Pooled risk estimates for the associations between total vitamin A and retinol and bladder cancer stratified by
study design, gender, geographical region, and source of intake
Subgroup Total vitamin A Retinol
RE (95% CI) Pheterogeneity (I
2 score) RE (95% CI) Pheterogeneity (I
2 score)
Study design
Cohort 0.86 (0.67, 1.03) 0.200 (33.1%) 0.91 (0.65, 1.17) 0.366 (0)
Case–control 0.78 (0.59, 0.97) 0.027 (60.4%) 0.87 (0.70, 1.04) 0.006 (60.9%)
Gender
Male 0.80 (0.66, 0.93) 0.160 (35.1%) 1.00 (0.69, 1.31) 0.067 (58.1%)
Female 0.68 (0.45, 0.91) 0.247 (27.6%) 1.51 (1.01, 2.00) 0.364 (0)
Geographical region
Europe 0.79 (0.24, 1.34) 0.040 (76.3%) 0.65 (0.62, 1.09) 0.138 (42.7%)
US/Canada 0.83 (0.68, 0.98) 0.047 (50.8%) 0.94 (0.74, 1.13) 0.047 (55.5%)
Japan 0.76 (0.45, 1.27) - 0.63 (0.38, 1.02) -
Source of intake
Diet 0.90 (0.80, 1.01) 0.426 (0) 0.87 (0.7, 1.04) 0.007 (60.3%)
Supplement 0.64 (0.47, 0.82) 0.568 (0) 0.80 (0.52, 1.23) -
Diet and supplement 0.80 (0.49, 1.12) 0.045 (62.7%) 0.72 (0.43, 1.00) 0.110 (54.8%)
Tang et al. World Journal of Surgical Oncology 2014, 12:130 Page 7 of 9
http://www.wjso.com/content/12/1/130toward the null. Despite this potential limitation, we
found strong inverse associations between blood levels
of retinol and some carotenoids and bladder cancer, which
indicated that our estimates are relatively conservative.
Heterogeneity is often a concern in a meta-analysis, and
we found a significant heterogeneity for total vitamin ATable 3 Pooled risk estimates for the associations
between carotenoids intake or blood carotenoids levels







P value (I2 score)
Carotenoids intake
Total carotenoids 4 0.67 (0.55, 0.79) 0.524 (0)
α-carotene 8 0.87 (0.76, 0.99) 0.221 (27.2%)
β-carotene 12 0.89 (0.82, 0.97) 0.084 (38.6%)
β-cryptoxanthin 6 0.86 (0.73, 1.00) 0.427(0)
Lutein/zeaxanthin 6 0.93 (0.70, 1.17) 0.035 (58.2%)




2 0.43 (0.20, 0.93) 0.241 (27.3%)
α-carotene 4 0.56 (0.37, 0.75) 0.106 (51.0%)
β-carotene 4 0.41 (0.05, 0.78) 0.013 (72.4%)
β-cryptoxanthin 4 0.62 (0.06, 1.19) 0.027 (67.4%)
Lutein/zeaxanthin 4 0.50 (0.12, 0.87) 0.056 (50.2%)
Lycopene 4 0.60 (0.17, 1.03) 0.053 (61.0%)and retinol intake. This may be due to the inherent meth-
odological differences, such as study design and different
ranges of exposure among studies. Although most studies
adjusted for known risk factors for bladder cancer (age,
sex, and smoking), residual or unknown confounding
cannot be excluded as a potential explanation for the
observed heterogeneity. Also, some studies measured
vitamin A intake from diet only, whereas other studies
combined dietary and supplemental vitamin A intake.
We used a random-effects model to try to mitigate the
heterogeneity as an issue, and our sensitivity analyses
did not change the results for total vitamin A and retinol
intake. We further performed stratified analyses by study
design, sex, geographical region, and source of intake.
Nevertheless, results were similar for total vitamin A and
retinol intake throughout the subgroups.
A major strength of our study is the large number of
included participants (11,580), and this is the first report
to pool REs of bladder cancer for each carotenoid. In
addition, our results were based on the adjusted evalu-
ation. However, several limitations should be mentioned.
First, as a meta-analysis of epidemiological studies, a
food-frequency questionnaire was used to estimate the
vitamin A intake, which may be influenced by the recall
and information bias. Second, the sample sizes for sev-
eral strata in the subgroup analyses were relatively small,
and these results should be interpreted with caution.
Finally, publication bias could be of concern because
small studies with null results tend not to be published,
though we found no evidence of publication bias in the
meta-analysis.
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Our results support the hypothesis that diets high in
vitamin A intake decrease the risk of bladder cancer.
However, given these limitations and the heterogeneity
of this meta-analysis, it is premature to recommend
higher dietary vitamin A for the primary prevention of
bladder cancer. Further investigation using large samples
and a rigorous methodology is warranted.
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